Unicycive Therapeutics and Their Upcoming Appearances
Unicycive Therapeutics, Inc., a pioneering clinical-stage biotechnology company dedicated to developing innovative therapies for kidney disease, is poised to make a significant impact at two upcoming investment conferences. The company's Chief Executive Officer, Shalabh Gupta, M.D., will engage with investors, sharing insights into their progress and future endeavors.
Details of the Noble Capital Markets Conference
One of the highlighted events is the Noble Capital Markets 20th Annual Emerging Growth Equity Conference. This event is a wonderful opportunity for Unicycive to present its corporate strategy and showcase its development pipeline to potential investors.
What to Expect at the Corporate Presentation
The corporate presentation is scheduled for December and is expected to start at 3:00 p.m. ET. Here, attendees can anticipate discussions regarding the company's innovative approach to treating kidney disease, alongside a deep dive into their product candidates.
Piper Sandler Conference: A Unique Fireside Chat
The second notable engagement is at the Piper Sandler 36th Annual Healthcare Conference, featuring an exciting fireside chat format. This session promises a more informal setting, allowing for dynamic interactions and discussions about the company’s strategic vision.
The Importance of the Fireside Chat
Taking place on December 5 at 12:30 p.m. ET, this chat holds great potential for Unicycive Therapeutics to connect authentically with its audience, fostering relationships while also providing insight into their upcoming projects and achievements.
Innovative Treatments and Clinical Advancements
Unicycive Therapeutics has been making notable strides with its lead drug candidate, oxylanthanum carbonate (OLC), which is currently under review by the U.S. Food and Drug Administration (FDA). This drug represents a promising advance in the treatment of hyperphosphatemia in patients suffering from chronic kidney disease.
Exciting Developments in Clinical Trials
Recent pivotal trial results for OLC were released, showcasing the efficacy of the treatment and the company’s commitment to addressing critical needs in kidney disease management. The anticipated New Drug Application (NDA) reflects their foothold in advancing kidney treatments.
Strong Intellectual Property and Future Prospects
Unicycive Therapeutics supports its innovations with a robust patent portfolio, safeguarding its intellectual property and ensuring continued development of its therapies. The company holds exclusivity on OLC's formulation until 2031, with potential extensions following FDA approval.
Exploring Second Assets: UNI-494
Additionally, Unicycive is advancing its second asset, UNI-494, a patent-protected new chemical entity currently in clinical development for acute kidney injury. This dedication to grassroots research emphasizes the company’s mission to cultivate comprehensive treatments across the renal pathology spectrum.
Engagement Opportunities and Investor Relations
For investors interested in learning more or setting up one-on-one meetings with management, representatives from Noble Capital Markets and Piper Sandler are available for contact. Establishing communication can further enhance understanding of Unicycive’s goals and ongoing projects.
Frequently Asked Questions
What is Unicycive Therapeutics known for?
Unicycive Therapeutics focuses on developing innovative therapies specifically aimed at treating kidney diseases.
When is Unicycive's participation in the upcoming investor conferences?
Unicycive is participating in two conferences, one on December 3 and another one on December 5.
What are the key products being discussed at the conferences?
Key products include oxylanthanum carbonate (OLC) for chronic kidney disease and UNI-494 for acute kidney injury.
How can investors contact Unicycive for meetings?
Investors can reach out to representatives from Noble Capital Markets or Piper Sandler to set up one-on-one meetings.
What is the significance of the FDA review for OLC?
The FDA review is critical as it could lead to the approval of OLC, providing a new treatment option for patients with kidney disease.
